BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

During the third quarter, Novavax entered into a material transfer agreement with a leading pharmaceutical company to ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s underwhelming market share for its COVID ...

Novavax Inc. closed $15.40 short of its 52-week high ($23.86), which the company achieved on June 6th. Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated ...

The company now expects $650 million to $700 million in revenue ... paired with milestone payments and royalties for 20 years ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

"We were hopeful to get a larger market share this year," Novavax CEO John Jacobs said in an interview, adding the company ...